Meeting
2018 ASCO Annual Meeting
Relapse prevention with second generation tyrosine kinase inhibitors for Ph+ve acute leukemia after allogenic stem cell transplantation.
Authors
Faiz K. Anwer
University of Arizona, Tuscon, AZ
Faiz K. Anwer , Zabih Warraich , Atif Sohail , Theresa Thai , Azka Latif , Vikas Kapoor , Keri Renee Maher , Faiza Hassan Warraich , Sami Warraich , Zeeshan Baig , Adeela Mushtaq , Pavan Tenneti , Ali McBride
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7050)
DOI
10.1200/JCO.2018.36.15_suppl.7050
Abstract #
7050
Poster Bd #
110
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by sequential use of nilotinib and imatinib: A GIMEMA protocol LAL 1408.
First Author: Cristina Papayannidis
Poster
2019 ASCO Annual Meeting
Allogeneic hematopoietic stem cell transplantation contributes to eradication of minimal residual disease in adult Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with dasatinib.
First Author: Jeremy Chang
Poster
2016 ASCO Annual Meeting
Survival outcomes of sustained MR4.5 in patients with chronic myeloid leukemia (CML) treated with various tyrosine kinase inhibitors (TKI).
First Author: Boyu Hu
Poster
2014 ASCO Annual Meeting
European leukemia net (ELN) 2013 response categories: Impact on clinical outcomes across four frontline tyrosine kinase inhibitor (TKI) modalities in chronic phase CML.
First Author: Preetesh Jain